Not long after Ocular Therapeutix Inc. unveiled positive phase I data in non-proliferative diabetic retinopathy with Axpaxli (axitinib intravitreal implant), Eyepoint Pharmaceuticals Inc. offered less-sunny phase II data from the Pavia trial testing Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in the same indication.
Randy Osborne is a staff writer for BioWorld Today, a publication focused on the biotechnology industry. With a talent for storytelling and a knack for creating new things, Randy's articles cover a wide range of topics within the biotech field, including company developments, clinical trials, and industry trends.